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1. Introduction 
Cancer is a group of diseases that leads to uncontrolled cell division and eventually forms a 
lump or mass called a tumor. They are classified and named after the part of the body where 
the tumor originates. Breast cancer begins in breast tissue, which is made up of glands for 
milk production, called lobules, and the ducts that connect lobules to the nipple. The 
remainder of the breast is made up of fatty, connective, and lymphatic tissue. On the basis of 
origin, it is of two types (i) ductal and (ii) lobular. Ductal carcinoma constitutes 80-90% and 
lobular carcinoma constitutes 10-20% breast cancer cases. 
Breast cancer is one of the most frequently diagnosed cancers in women worldwide, 
comprising 16% of all female cancers cases. It is estimated that this disease will affect one in 
eight females in America during their lifetime. It is estimated that occurrence of female 
breast cancer is 28% of cancers from all sites in U.S.A, and the relative risk of ever 
developing breast cancer is 0.125 (1 in 8) (American Cancer Society, 2009). Although breast 
cancer is thought to be a disease of the developed world, a majority (69%) of all breast 
cancer deaths occurs in developing countries (WHO Global Burden of Disease, 2004) and 
relative survival is poor in underdeveloped and developing countries (Coleman et al., 2008). 
The relative risk of developing breast cancer in the lifetime of women in the developed and 
developing countries is 0.048 (1 in 21) and 0.018 (1 in 56) respectively. In India, breast cancer 
is the leading cancer among women (Fig. 1) and the relative risk is 0.033 (1 in 30) (NCRP, 
2008). 
2. Risk factors of breast cancer 
Every woman is at risk for developing breast cancer. Several relatively strong risk factors for 
breast cancer that affect large proportion of the general population have been known for 
some time. However, the vast majority of breast cancer cases occur in women who have no 
identifiable risk factors other than their gender and age (Kelsey & Gammon, 1990). The other 
established risk factors are previous family history, age at first full-term pregnancy, early 
menarche, late menopause, genetic and breast tissue density. These factors are not easily 
modifiable and classified under unmodified factors. However, other factors associated with 
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increased breast cancer risk are postmenopausal obesity, hormone replacement therapy 
(HRT), alcohol consumption, and physical inactivity, no breast feeding are modifiable and 
classified under modified factors. The relative risk of various factors responsible for breast 
cancer are shown in Table 1 (Hulka & Moorman, 2001). 
 
 
Fig. 1. Demographic profiles of cancer cases in Indian females. Based on 2004-2005 data for 
Bangalore, Barshi, Bhopal, Chennai, Delhi, Mumbai, Ahmedabad and 2005 data for Kolkata. 
3. Classification of breast cancer 
3.1.1 Histopathological classification 
Each breast has 15 to 25 sections called lobes, formed by groups of lobules, the milk glands. 
Each lobule is composed of grape-like clusters of acini (also called alveoli), the hollow sacs 
that make and hold breast milk. The lobes and lobules are connected by thin tubes, called 
ducts that deliver milk to nipple (Fig. 2). The pink or the brown pigmented region 
surrounding the nipple is called areola. Connective and fatty tissue fills the remaining space 
in between the lobes and ducts. The most common type of breast cancer is ductal cancer. It is 
found in the cells of the ducts. Cancer that starts in lobes or lobules is called lobular cancer. 
It is more often found in both breasts than other types of breast cancer. Rarely breast cancer  
 
 
Fig. 2. Anatomy of female breast. 
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can begin in the connective tissue that's made up of muscles, fat and blood vessels. Cancer 
that begins in the connective tissue is called sarcoma. It accounts for less than 5% of all soft 
tissue sarcomas and less than 1% of breast cancer (Moore and Kinne, 1996). Phyllodes tumor 
and angiosarcoma are two common forms of sarcoma. Cancers are also classified as non 
invasive (in situ) and invasive (infiltrating). The term in situ means “in its original place” 
and refers to cancer that has not spread past the area where it initially developed. Invasive 
breast cancer has a tendency to spread (invade) to other tissues of the breast and/or other 
regions of the body. A less common type of breast cancer is inflammatory breast cancer 
characterized by general inflammation (red and swollen) of the breast (Fig. 3). The different 
types of invasive cancers, their frequency and percentage survival is shown in Table 1.2.  
 
Relative Risk Factor 
>4.0 
Female 
Age (65+ vs. <65 years, although risk increases across all ages until 
age 80) 
Certain inherited genetic mutations for breast cancer (BRCA1 
and/or BRCA2) 
Two or more first-degree relatives with breast cancer diagnosed at 
an early age 
Personal history of breast cancer 
High breast tissue density or 75% dense 
2.1-4.0 
Biopsy-confirmed atypical hyperplasia  
One first-degree relative with breast cancer  
High-dose radiation to chest  
High bone density (postmenopausal)  
1.1-2.0 
Factors that affect 
circulating 
hormones 
Late age at first full-term pregnancy (>30 years)  
Early menarche (<12 years)  
Late menopause (>55 years)  
No full-term pregnancies  
No breast feeding  
Recent oral contraceptive use  
Recent and long-term use of HRT  
Obesity (postmenopausal)  
Personal history of endometrial or ovarian cancer  
1.1 -2.0 
Other factors 
Alcohol consumption  
Height (tall)  
High socioeconomic status  
Hulka BS, and  Moorman PG 2001. Maturitas 2008; 38:103-113 
© 2001 Elsevier Science Ireland Ltd. 
Table 1. Factors that increase the Relative Risk for Breast Cancer. 
Invasive ductal carcinoma is the most common breast cancer and it accounts more than 75% 
of breast cancer cases. Most are invasive ductal carcinoma (IDC) not otherwise specified 
(IDC NOS), and remaining IDC includes Inflammatory breast cancer, medullary carcinoma, 
metaplastic, apocrine and tubular carcinoma. Medullary carcinoma accounts <5% of breast 
cancers diagnosed, and takes its name from its color, which is close to the color of brain 
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tissue, or medulla. It is an invasive breast cancer that forms a distinct boundary between 
tumor tissue and normal tissue. Metaplastic breast cancer is a form of invasive ductal 
cancer, meaning that it forms in the milk ducts and then moves into other tissues of the 
breast. Metaplastic breast carcinomas constitute a heterogeneous group of neoplasms, 
accounting for less than 1% of all invasive mammary carcinomas (Reis-Filho et al., 2005), 
such as squamous (skin) or osseous (bone) cells. The other groups of invasive breast cancers 
are invasive lobular carcinoma, adenoid cystic carcinoma, micropapillary carcinoma, 
mucinous carcinoma (formed by the mucus-producing cancer cells), etc as shown in Fig. 3.  
 
 
Fig. 3. Histology of breast carcinoma. Breast carcinoma is classified into Ductal (A), Lobular 
carcinoma (B) and Inflammatory carcinoma. (C). It can be further classified into non-
invasive (A-B) and invasive carcinoma (C-L). Invasive cancer includes Inflammatory (C), 
Invasive lobular (D), tubular (E) apocrine (F), medullary, (G) metaplastic (H), 
micropapillary, (I) adenoid cystic (J), mucunous carcinoma (K), and paget disease (L). 
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Histopathological type of invasive 
breast carcinoma 
Frequency (%) 10-year OS (%) 
Invasive ductal carcinoma not otherwise 
specified (IDC NOS) 
50-60 35-50 
Inflammatory carcinoma 1-6 30-40 
Apocrine carcinoma 1–4 Like IDC NOS 
Medullary carcinoma 5–7 50–90 
Metaplastic carcinoma <5 Unknown 
Micropapillary carcinoma 1-2  Unknown 
Tubular carcinoma 1–2 90–100 
Invasive lobular carcinoma 5–15 35–50 
Adenoid cystic carcinoma 0.1 85–100 
Mucinous carcinoma <3 85–95 
Neuroendocrine carcinoma 2–5 Unknown 
Mammary Paget disease 1-4 40-50 
Table 2. Frequency and outcome of histological types of invasive breast cancer. 
3.1.2 Molecular classification 
Breast cancer is a clinically heterogeneous disease. Histologically similar tumors may have 
different prognosis and may respond to therapy differently. It is believed that these 
differences in clinical behavior are due to molecular differences between histologically 
similar tumors. DNA microarray technology, Immuno-histochemistry (IHC), Fluorescent in 
situ hybridization (FISH), and quantitative reverse transcription polymerase chain reaction 
(RT-PCR) are ideally suitable techniques to reveal molecular differences among the same or 
different groups of histopathological specimens. Each of these molecular techniques has the 
potential for proper prognosis and prediction of human cancers, including breast. IHC was 
developed more than 30 years back and it is used for classification of breast cancer into ER 
positive and ER negative tumors. FISH was developed 20 years back and is used to classify 
breast tumors into HER-2 amplified or non amplified categories. Breast cancer cells 
generally overexpress estrogen receptor (ER)/ progesterone receptor (PR), and human 
epidermal growth factor-2 (HER-2) receptor for breast tumor formation and progression. 
Thus, breast cancer can be classified into three sub-groups (i) ER/PR positive (ii) ER 
negative or HER-2 positive and triple negative (ER, PR and HER-2 negative) on the basis of 
receptor status. The classification of breast cancer on the basis of ER status improves the 
prognosis and clinical outcome of ER+ tumors as ER+ cancer cells depend on estrogen for 
their growth, and the treatment of patients with anti-estrogen agents (e.g. tamoxifen) will 
inhibit the effect of estrogen and thus improves the treatment outcome. Generally, HER-2+ 
had a worse prognosis, however HER-2+ cancer cells respond to drugs such as the 
monoclonal antibody, trastuzumab, (in combination with conventional chemotherapy) and 
this has improved the prognosis and pathological complete response significantly (Chang et 
al., 2010). Triple-negative breast cancer is a high risk breast cancer that lacks the benefit of 
specific therapy that targets these proteins. It can be categorized in basal subtypes (Rakha et 
al., 2007). It is found in 10-20% of breast cancer cases and mostly diagnosed in younger 
women with BRCA1 and BRCA2 mutations (Dent et al., 2007; Dawood et al., 2009). The rate 
of recurrence is very high, and it reaches its peak within first 3 years and then declines after 
that. Patients with triple negative breast cancer are most likely to die within 5 years than 
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patients with other breast cancers. All deaths due to breast cancer in patients’ with triple-
negative cancer occurred within 10 years of diagnosis. 
A novel molecular classification of breast cancer based on gene expression profiles 
segregates breast cancer into four types (i) luminal, (ii) basal, (iii) HER-2 and (iv) normal 
type (Perou et al., 2000; Sotiriou et al., 2003; Tamimi et al., 2008) (Fig. 4). 
 
 
Fig. 4. Dendrogram of breast cancer. The tumors were separated into two main groups 
mainly associated with ER status as analyzed by hierarchical cluster analysis generated by 
using gene profile data. The dendrogram is further branched into smaller subgroups within 
the ER+ and ER- classes based on their basal and luminal characteristics: HER-2 subgroup, 
dark red; basal-like 1 subgroup, pink; luminal-like A subgroup, green; luminal-like B 
subgroup, yellow; and normal-like breast subgroup, blue. 
Luminal express keratin 8/18, ER, GATA binding protein, X-box binding protein 1, annexin 
XXXI, cytochrome P450 and basal type express keratin 5, keratin 17, integrin ┚4, matrix 
metalloprotease 14, laminin ┙3, basonuclin and mutated TP53 gene. Luminal type is further 
classified into luminal A and luminal B. Luminal B expresses HER-2 along with ER where as 
luminal A doesn’t express HER-2. HER-2 subtype express ERB-2/HER-2, growth factor 
receptor bound protein 7, TNF receptor-associated factor IV, GRB 7. Normal–breast-like 
group showed the highest expression of many genes known to be expressed by adipose 
tissue and other non-epithelial cell types. These tumors also showed strong expression of 
basal epithelial genes and low expression of luminal epithelial genes. It expresses CD36 
antigen collagen type I, glycerol 3 phosphate dehydrogenase I, lipoprotein lipase A, alcohol 
dehydrogenase 2 (Sorlie et al., 2001). The molecular subclasses show difference in clinical 
outcome as per as overall survival (OS) and relapse free survival (RFS) is concerned as 
shown in Table 1.3. There was a significant difference in overall survival between the 
subtypes with basal and HER-2 is as associated with worse outcome and shortest survival 
time. 
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Molecular 
types of breast 
carcinoma 
Frequency 
(%) 
5-year OS+ 
(%) 
5-year RFS* 
(%) 
10-year 
OS (%) 
10-year 
RFS (%) 
Luminal A 50-60 85-95 80-90 75-85 75-85 
Luminal B 5-10 70-80 65-75 55-65 54-64 
Basal 10-20 63-73 60-70 57-67 45-55 
ERB-2 10-20 55-65 15-20 45-55 15-30 
Normal-like 10-15 84-94 80-90 75-85 72-82 
Table 3. Breast cancer outcomes in molecular types of breast cancer.RFS: The percentage of 
people without any further symptoms of breast cancer during the interval elapsed between 
the date of breast surgery and the date of diagnosed further episode of breast cancer, 
whether the breast cancer was classified as a recurrence or second primary, and whatever 
the histology. OS: The percentage of people survived during the interval elapsed between 
the date of breast surgery and the date of breast cancer-related or un-related death 
(documented from hospital records). 
4. Clinical outcomes of breast cancer in association with clinical, 
histopathological and molecular classification 
Breast cancers can be classified by different schemata. Classification aspects include clinical 
(age, tumor, node), histopathological (grade, ER and HER-2 status, ductal, lobular, invasive) 
and molecular (normal-like, luminal, basal, HER-2) values. Every aspect influences 
treatment response and prognosis as shown in Table 2 and Table 3. The true prognostic or 
predictive value of the various molecular classes is unknown because there is a strong 
correlation between molecular class and conventional histopathologic variables (ER status, 
grade). For example, in one study, all luminal-type cancers were ER-positive and 63% of 
these were also low or intermediate grade, in contrast to 95% of basal-like cancers that were 
ER-negative, 91% of which were high grade (Pusztai et al., 2003). These associations partly 
explain the different clinical outcome observed in different molecular classes. Rouzier et al. 
studied the pathological outcomes of different molecular subclasses of breast cancer 
patients. They obtained tumor tissue biopsies from 82 patients with newly diagnosed breast 
cancer before they were given a commonly used chemotherapy (Taxol/5-fluorouracil, 
doxorubicin, and cyclophosphamide). Patients with basal-like and erbb-2+ subgroups were 
found to have the highest rates (45% each) of a pathological complete response (CR), while 
only 6% of luminal tumors had a complete response. Among the normal-like cancers, no 
response was seen (Rouzier et al., 2005). None of the 61genes associated with pathologic CR 
in the basal-like group were associated with pathologic CR in the HER-2+ group, which 
suggest that the mechanisms of chemotherapy sensitivity may vary across the subtypes. As 
molecular classification was not independently associated with pathologic CR, the 
predictive accuracy of the logistic regression models including (a) clinical + pathologic 
variables, (b) clinical variables + molecular classification, and (c) clinical + pathologic 
variables + molecular class (Fig. 5) was measured by constructing Receiver Operating 
Characteristics curve.  
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Source of the curve AUC     95% CI     p           
Clinical and pathological 0.84     0.73-0.95     <0.001
Clinical variables and 0.82     0.72-0.92     <0.001
molecular classification
Clinical, pathological and 0.89     0.81-0.97     <0.001
molecular classification
Reference line
Rouzier R et al. Clin Cancer Res 2005;11: 5678-5685
© by 2005 American Association for Cancer Research  
 
Fig. 5. Receiver Operating Characteristic curves for logistic regression models. Three 
different prediction models were compared including clinical plus histopathologic variables 
(model 1), clinical variables plus molecular classification (model 2), and clinical plus 
histopathologic plus molecularclassification (model 3). All three models were similarly 
done. 
The three models yielded similar area under curve (AUC). This indicates that the molecular 
class alone can replace histopathological characteristics (estrogen receptor, HER-2 status, or 
grade) for prediction of pathologic CR but provides little additional information when these 
characteristics are included. The basal-like and HER-2 tumors were predominantly high 
nuclear grade and the basal-like tumors were almost all estrogen receptor negative and 80% 
of HER-2 molecular class expresses HER-2. These characteristics are known to be associated 
with higher likelihood of pathologic CR to preoperative chemotherapy (Rouzier et al., 2002; 
Abrial et al., 2005; Gennari et al., 2008). Because of this association, incorporation of 
molecular class into a logistic regression–based predictor of response didn’t improve the 
prediction accuracy compared with using routine clinical and pathologic variables only. 
Therefore, it is likely that more focused gene signature–based predictors will need to be 
developed through supervised outcome prediction methods that are differentially expressed 
between cases of pathologic CR and residual disease. 
5. Screening and detection of breast cancer 
Screening uses test/techniques to check people who might have that disease (breast cancer) 
and to allow it to be treated at an early stage when a cure is more likely. Breast cancer 
screening is done by mammography (low dose x-ray technique to visualize the internal 
structure of the breast). On average, mammography will detect about 80-90% of the breast 
cancers in women without symptoms. Testing is somewhat more accurate in 
postmenopausal than in premenopausal women (Michaelson et al., 2002). It can reduce 
breast cancer mortality by 20-30% in women over 50 yrs old in high-income countries when 
the screening coverage is over 70% (IARC, 2008). MRI, or magnetic resonance imaging, is a 
technology that uses magnets and radio waves to produce detailed cross-sectional images of 
the inside of the body. MRI does not use x-rays, so it does not involve any radiation 
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exposure. Breast MRI is not recommended as a routine screening tool for all women as MRI 
screening results in more false positives results. However, it is recommended for screening 
women who are at high risk for breast cancer, usually due to a strong family history and/or 
a mutation in genes such as BRCA1 or BRCA2. It is also used for gathering more 
information about the suspicious area found on mammogram and ultrasound and also used 
for monitoring recurrence after treatment. Positron emission tomography (PET) scan creates 
computerized images of chemical changes that take place in the tissue. PET scans may play 
a role in determining whether a breast mass is cancerous. However, PET scans are more 
accurate in detecting larger and more aggressive tumors than they are in locating tumors 
that are smaller than 8 mm and/or less aggressive. They may also detect cancer when other 
imaging techniques show normal results. PET scans may be helpful in evaluating and 
staging recurrent disease. Clinical breast examination (CBE) is recommended for average 
risk asymptomatic in the age group of 20-30 to observe any changes in shape, texture, and 
location of lumps (situated in skin or deeper tissues). The breasts should also be inspected 
for skin changes (e.g., dimpling, redness) and asymmetry. The area under both arms will 
also be examined. CBE is also an opportunity for a woman and her health care provider to 
discuss changes in her breasts, early detection testing, and factors in the woman’s history 
that might make her more likely to develop. All women should become familiar with both 
the appearance and feel of their breasts to detect any changes and report them promptly to 
their physician. A woman who chooses to perform breast self-exams (BSE) should receive 
instructions and have her technique reviewed by a health care professional who performs 
clinical examinations. Finding and reporting breast changes early offers women the best 
opportunity for improving breast cancer treatment and reducing breast cancer deaths. 
Mammotome® is a vacuum assisted breast biopsy that uses image guidance such as 
stereotactic x-ray, ultrasound, MRI and/or molecular imaging to perform breast biopsies. 
Mammotome offers a full array of tissue markers to mark the biopsy site for follow-up 
observations. There have been no reports of serious complications resulting from the 
Mammotome breast biopsy system. Ductal lavage is another screening and investigational 
technique for collecting samples of cells from breast ducts for analysis under a microscope. 
A saline (salt water) solution is introduced into a milk duct through a catheter (a thin, 
flexible tube) that is inserted into the opening of the duct on the surface of the nipple. Fluid, 
which contains cells from the duct, is withdrawn through the catheter. The cells are checked 
under a microscope to identify changes that may indicate cancer or changes that may 
increase the risk for breast cancer. The procedure is used to identify precancerous cells, 
called atypical cells. Ductal lavage is currently performed only on women who have 
multiple breast cancer risk factors to detect breast cancer before it starts. Ductal lavage 
appears to have low sensitivity and high specificity for breast cancer detection, possibly 
because cancer-containing ducts fail to yield fluid or have benign or mildly atypical 
cytology (Khan et al., 2004). 
6. Breast cancer treatment 
Breast cancer treatment depends on stage, age, hormonal and receptor status. Most women 
with breast cancer will undergo some type of surgery. Surgery is often combined with other 
treatments such as radiation therapy, chemotherapy, hormone therapy, and targeted 
therapy. 
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6.1 Surgery 
Most patients with breast cancer have surgery to remove the tumor mass from the breast. 
The types of breast cancer surgery differ in the amount of tissue that is removed with the 
tumor, depending on the tumor's characteristics, whether it has spread (metastasized), and 
patient’s personal feelings. Some of the lymph nodes under the arm are usually taken out 
and looked under a microscope to see if they contain cancer cells. Breast-conserving surgery 
or lumpectomy is done to remove the cancer cells but not the breast itself. Lumpectomy is 
almost always followed by about 5 to 7 weeks of radiation therapy. A woman who chooses 
lumpectomy and radiation will have the same expected long-term survival as if she had 
chosen mastectomy (Fisher et al., 2002). Simple or total mastectomy includes removal of the 
entire breast. Modified radical mastectomy includes removal of the entire breast and lymph 
nodes under the arm, but does not include removal of the underlying chest wall muscle, as 
with a radical mastectomy. Both lumpectomy and mastectomy are often accompanied by 
removal of regional lymph nodes from the axilla, or armpit, to determine the involvement of 
lymph nodes and spreading of the disease. Axillary lymph node metastasis is the most 
important prognostic factor for the disease-free and overall survival. Patients with multiple 
unfavorable risk factors such as positive axillary lymph nodes, high nuclear grade, young 
age and large tumor showed poorer local control and disease-free survival than patients 
without any risk factors, and so more aggressive treatment is required for these patients. 
Adjuvant radio-, chemo-, or targeted therapy has improved the prognosis of patients with 
higher risk factors (Lee & Chan, 1984; Kim et al., 2005). 
6.2 Radiation therapy  
Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of 
radiation to destroy cancer cells remaining in the breast, chest wall, or underarm area after 
surgery, or to reduce the size of a tumor before surgery (Early Breast Cancer Trialists' 
Collaborative Group, 2000). There are two types of radiation therapy. External radiation 
therapy uses a machine outside the body to send radiation toward the cancer. Internal 
radiation therapy uses a radioactive substance sealed in needles, seeds, wires, or catheters 
that are placed directly into or near the cancer. The way the radiation therapy is given 
depends on the type and stage of the cancer being treated. Using traditional clinical and 
pathological factors, patients can be classified into subgroups by the risk of loco-regional 
recurrence. In the high-risk groups the absolute benefit of irradiation is larger. However, the 
patients are over-treated in every subgroup. Substantial proportion of the patients remains 
free of loco-regional recurrence even in the absence of irradiation, and some patients 
develop loco-regional recurrence despite postoperative irradiation. Molecular subtypes on 
the basis of receptors may provide sufficient information to allow accurate individual risk 
assessment to identify patients who might benefit from receiving post mastectomy 
radiotherapy (PMRT). A significantly improved overall survival after PMRT was seen only 
among patients of luminal subtypes. No significant overall survival improvement after 
PMRT was found among patients with basal and ERB2 subtypes (Fig. 6). There was also 
smaller improvements in loco-regional recurrence of breast cancer in basal and ERB2 
subtypes as compared to luminal A and luminal B (Kyndi et al., 2008). Hence, the 
improvement in survival resulting from the use of irradiation is more related to the 
prevention of local recurrences. Post-irradiation local recurrence increases the risk of 
mortality, but with good prognostic factors (<4 positive nodes, tumor size <2 cm, Grade 1 
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malignancy, ER- and PR-positive, HER-2-negative) the 10-year survival is 80-90% (Fodor, 
2009).  
 
 
Fig. 6. Overall survival (OS)% of different molecular subtypes of breast cancer patients after 
receiving post mastectomy radiation therapy (RT). P values and 95% CI of Hazard (H) ratios 
are shown. 
6.3 Chemotherapy and molecular targeted-therapy 
Chemotherapeutic drugs are applied in neoadjuvant settingsto shrink the size of tumor that 
has metastasized and also in adjuvant settings to delay the further growth and spread of the 
tumor. It is found that combinations of drugs are more effective than just one drug alone for 
breast cancer treatment. The most common drugs recommended to be used in combination 
in early breast cancer are cyclophosphamide, methotrexate, 5-fluorouracil (CMF 
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combinations), doxorubicin (Adriamycin), epirubicin, paclitaxel (Taxol), and docetaxol 
(Taxotere). Although the benefit and clinical outcome of chemotherapy is dependent on 
clinical and histopathological parameters, but there are a percentage of cases that behave in 
an unexpected manner, even if the clinical and pathological parameters indicate the 
opposite (Gonzalez-Angulo et al., 2007). The introduction of hormonal receptor status to the 
classical clinical parameters improved the clinical outcome (Goldhirsch et al., 2003). The 
chemotherapeutic drugs are designed to target the specific molecular markers (molecular 
targeted therapy) overexpressed in cancer tissues. The presence of ER is correlated with a 
better prognosis, predicting response to hormonal therapies such as tamoxifen and 
aromatase inhibitors. But still 15-20% of breast cancer patients with ER+ have recurrent 
disease. It’s the luminal B subgroup of previously classified ER+ tumor that is irresponsive 
to tamoxifen treatment as they co-express EGFRs and shows poor relapse-free survival 
(RFS) and over-all survival (OS). Thus over-simplified classification based on ER status 
required additional molecular makers for sub-classification for optimal treatment. The 
molecular portraits based on gene profiling divides breast carcinomas into luminal (A and 
B), basal, HER-2 and normal like. Basal and HER-2 types normally overexpress EGFR and 
HER-2 respectively. EGFR and HER-2 is overexpressed in 17-30% and 20-30% respectively 
in breast cancer. Both EGFR and HER-2 is associated with poor prognosis and worse clinical 
outcome. Basal like subtypes are more aggressive and less responsive to conventional 
chemotherapy and expected to benefit from EGFR-targeted therapies. Tyrosine kinase 
inhibitors (TKI) (ZD1839, ZD6474) in combined with anthracyclines (doxorubicin, 
epirubicin) or taxanes based regimens will improve the clinical outcome of the basal 
subtypes. HER-2 might serve as a marker for tissue HER-2 status, especially for the 
prediction of benefit from trastuzumab and/or chemotherapy regimens (anthracyclines) 
(Sandri et al., 2004). Although the molecular profile of the tumor is a major determinant of 
disease progression and response to treatment, other factors including chemo- sensitvity or 
resistivity may be of considerable importance. It is found that for 100 node-negative, 
premenopausal women receiving chemotherapy according to standard criteria, at 5 years 3 
are cured by chemotherapy, 83.50 would have been alive without chemotherapy and 13.50 
die despite chemotherapy. With application of molecular profiling to predict the outcome 
(for the same 100 people), the number treated would be reduced to 39.05 (allowing for a 
false-positive rate equivalent to that seen in the van ‘t Veer study (van 't Veer et al., 2002), 
resulting in an increase in the proportion cured (from 3 out of 100 to 3 out of 39 or 8%). If it 
were possible to predict chemo-responsiveness, it is possible that the number receiving 
chemotherapy would reduce further from 39.05 to 29.20 (allowing for a false-positive rate 
equivalent to that seen in the van‘t Veer study). In this scenario, the proportion cured by 
chemotherapy would be 3 out of 29.20 (10.16%) (>3-fold increase in survival rate using 
chemotherapy), and the number of women treated has been reduced by 70.80%. Thus it is 
found that molecular profiling will enhance the survival benefit of chemotherapeutic 
regimens, which will be further improved applying the knowledge of chemo-responsiveness 
as shown in Fig. 7. If accurate determination of chemo-sensitivity were achieved by 
observing the set of genes responsible for treatment response, the overall number receiving 
cytotoxic treatment unnecessarily would decrease, and the overall survival benefit derived, 
per person treated, increase accordingly, as shown in Fig. 7. However, the absolute survival 
benefit of patients diagnosed with breast cancer would be unaffected and would be 
improved with more molecular subtypes along with the development of specific agents 
targeting particular biomarkers (molecular targeted therapy). 
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Fig. 7. Model for the effect of molecular profiling on breast cancer. The data shows numbers 
of premenopausal women with node negative breast cancer receiving chemotherapy (CT), 
and associated benefit at 5 years. 100 node-negative, premenopausal women receiving 
chemotherapy according to standard criteria, at 5 years showed survival benefit, no benefit 
and breast cancer specific death. The two bar graph represents absolute survival benefit and 
% survival benefit of breast cancer patients receiving chemotherapy. Note that in neither 
figure has consideration been given to the false-negative rate inherent in molecular 
profiling. It has been assumed that all deaths occurring were breast cancer related. 
7. Conclusion 
Adjuvant chemo- and radiotherapy improves survival of patients but it is being increasingly 
recognized that the benefit is not equal for all patients of breast cancer. Molecular 
characteristics of the cancer affect sensitivity to chemo- and radiotherapy. In general, ER- 
(Basal and HER-2) is more sensitive to chemotherapy than ER+ (Luminal A and Luminal B) 
breast cancer where as ER+ is more sensitive to radiotherapy than ER- breast cancer. The 
prognostic predictions made by traditional histopathological based models and molecular 
based models are discordant in about 30% of the cases (van de Vijver et al., 2002), suggesting 
that one of these methods may be superior to the other or at least that the information they 
capture is complementary. Corollary to this, it is found that when both the type of 
classifications are combined (histopathological and molecular), it yield better prognostic 
values as observed in Fig. 6. It is currently unknown whether genomic tests based on 
molecular signatures yield a more accurate risk prediction than conventional models. A 
better prognostic test based on molecular classification with the knowledge of chemo-
responsiveness could lead to a reduction in overtreatment of low-risk individuals who are 
falsely assigned to high-risk category by clinical variables. Such a test could also lead to 
better overall survival by correctly identifying high-risk individuals who might currently 
miss out on systemic therapy. Even if molecular classification do not prove to be better than 
clinical models in prognosis and prediction outcome of breast cancer, inclusion of their 
results, as additional variables, in current models could improve prognostic predictions. 
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